CG01 / CombiGene, Roche - LARVOL DELTA

Analysis guide: Global licensing agreement with Roche on CG01 [Google translation] (Cision) - "Phase 1/2 study on epilepsy patients with CG01 2022; CombiGene will in 2021 have a clear focus on conducting the final preclinical studies for the gene therapy project CG01 against drug-resistant focal epilepsy, which includes biodistribution and safety studies. The first clinical phase 1/2 study in humans with CG01 that has blockbuster potential is expected to begin in 2022."

New P1/2 trial • CNS Disorders • Epilepsy

Spark Therapeutics and CombiGene Enter into Exclusive, Global Licensing Agreement for Gene Therapy Candidate CG01 (GlobeNewswire) - "Spark Therapeutics...and CombiGene AB...today announced the signing of an exclusive collaboration and licensing agreement for CombiGene’s CG01 project, an investigational gene therapy which aims to treat drug resistant focal epilepsy. The agreement provides Spark with the exclusive, worldwide license to develop, manufacture and commercialize CG01. CombiGene will continue to execute certain aspects of the preclinical program in collaboration with Spark."

Licensing / partnership • CNS Disorders • Epilepsy